We serve Chemical Name:Beryllium chloride hexahydrate CAS:56491-82-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Beryllium chloride hexahydrate
CAS.NO:56491-82-8
Synonyms:Beryllium chloride, hexahydrate
Molecular Formula:BeCl2H12O6
Molecular Weight:188.01000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:55.38000
Exact Mass:187.01300
LogP:1.21820
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Beryllium chloride, hexahydrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Beryllium chloride, hexahydrate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Beryllium chloride, hexahydrate Use and application,Beryllium chloride, hexahydrate technical grade,usp/ep/jp grade.
Related News: With over 80 years of experience developing and manufacturing small molecules, UQUIFA has not only the knowledge and tools to successfully execute transfer activities but also the track record of success with several crucial drug commercialization,” Gurnurkar says. Dehydrogenase, glyceraldehyde phosphate (Botrytis aclada strainPRI006 gene g3pdh fragment) manufacturers The Company intends to further develop candidates from Mindset Families 2-4 with the goal of selecting additional lead candidates in the near future. 5-(4-Methoxy-phenyl)-1-phenyl-3-(3,4,5-trimethoxy-phenyl)-3a,6a-dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. tert-butyl 4-(3-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)benzyl)piperidine-1-carboxylate vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. tert-butyl 4-(3-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)benzyl)piperidine-1-carboxylate vendor & factory.
